SCHEMBL2869622

SCHEMBL2869622

Cc1ccc(CC2CNCC3C(=O)OC(c4cccc(F)c4)(c4cccc(F)c4)N23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.37
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
KCNN4 O15554 1/20 0.33
LMNA P02545 2/20 0.33
THRB P10828 2/20 0.33
MAPT P10636 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
ALDH1A1 P00352 2/20 0.32
CHRNA1 P02708 1/20 0.32
CHRNB1 P11230 1/20 0.32
CHRNB2 P17787 1/20 0.32
SLC6A2 P23975 1/20 0.32
CHRNB4 P30926 1/20 0.32
SLC6A4 P31645 1/20 0.32
CHRNA3 P32297 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861668 0.87 NPSR1 (0.33) ATMNPSR1ALDH1A1SLC6A2SLC6A4
SCHEMBL2866028 0.81 NPSR1 (0.40) NPSR1SLC6A2SLC6A4SLC6A3
SCHEMBL2856685 0.74 NPSR1 (0.49) NPSR1KCNN4THRBALDH1A1
SCHEMBL2868959 0.69 NPSR1 (0.40) NPSR1KCNN4OPRM1
SCHEMBL2871764 0.69 NPSR1 (0.48) NPSR1TP53ALDH1A1
SCHEMBL2864855 0.69 KCNN4 (0.37) NPSR1KCNN4OPRM1OPRL1ALDH1A1
SCHEMBL6039852 0.69 NPSR1 (0.36) NPSR1POLBKCNN4MAPTALDH1A1
SCHEMBL2861757 0.69 NPSR1 (0.47) KDM4ENPSR1LMNATHRBALDH1A1
Hydrochloric Acid SCHEMBL2861673 0.68 NPSR1 (0.35) NPSR1POLBKCNN4MAPTALDH1A1
SCHEMBL2871880 0.66 NPSR1 (0.40) KDM4ENPSR1TP53LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 ATM 3450/4885KDM4E 2385/4885NPSR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.